Please use this identifier to cite or link to this item:
Title: Real-life cost-effectiveness of benralizumab in patients with severe asthma.
Authors: Padilla-Galo, A
García-Ruiz, A J
Levy Abitbol, R Ch
Olveira, C
Rivas-Ruiz, F
García-Agua Soler, N
Pérez Morales, M
Valencia Azcona, B
Tortajada-Goitia, B
Moya-Carmona, I
Levy-Naon, A
Keywords: Asthma;Benralizumab;Biologics;Cost-effectiveness;Economic impact;Eosinophils;Real-life;Severe asthma
metadata.dc.subject.mesh: Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
Cost-Benefit Analysis
Cross-Sectional Studies
Disease Progression
Drug Costs
Follow-Up Studies
Forced Expiratory Volume
Middle Aged
Patient Acuity
Treatment Outcome
Issue Date: 27-May-2021
Abstract: Availability of clinically effective and cost-effective treatments for severe asthma would be beneficial to patients and national healthcare systems. The aim of this study was to evaluate clinical outcomes and healthcare expenditure after incorporating benralizumab into the standard treatment of refractory eosinophilic asthma. This was a cross-sectional multicentre study of consecutive patients with refractory eosinophilic asthma who received treatment with benralizumab during at least 12 months. Patient follow-up was performed in specialised severe asthma units. The main effectiveness parameters measured were: the avoidance of one asthma exacerbation, a 3-point increase in the asthma control test (ACT) score, and the difference in utility scores (health-related quality of life) between a 1-year baseline treatment and 1-year benralizumab treatment. The health economic evaluation included direct costs and incremental cost-effectiveness ratios (ICERs). After 1 year of treatment with benralizumab, patients with refractory eosinophilic asthma showed an improvement in all the effectiveness parameters analysed: improvement of asthma control and lung function, and decrease in the number of exacerbations, oral corticosteroid (both as corticosteroid courses and maintenance therapy), and inhaled corticosteroid use. The total annual cost per patient for the baseline and benralizumab treatment periods were €11,544 and €14,043, respectively, reflecting an increase in costs due to the price of the biological agent but a decrease in costs for the remaining parameters. The ICER was €602 per avoided exacerbation and €983.86 for every 3-point increase in the ACT score. All the pharmacoeconomic parameters analysed show that treatment with benralizumab is a cost-effective option as an add-on therapy in patients with refractory eosinophilic asthma.
metadata.dc.identifier.doi: 10.1186/s12931-021-01758-0
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC8155800.pdf1,71 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons